34 related articles for article (PubMed ID: 16344915)
1. Effect of Neoadjuvant Concurrent Chemoradiation on Operability and Survival in Locally Advanced Inoperable Breast Cancer.
Iyer P; Krishnamurthy A; Velusamy S; Sundersingh S; Rajaram S; Balasubramanian A; Radhakrishnan V
Int J Radiat Oncol Biol Phys; 2024 May; 119(1):163-171. PubMed ID: 38036271
[TBL] [Abstract][Full Text] [Related]
2. The role of PET and MRI in evaluating the feasibility of skin-sparing mastectomy following neoadjuvant therapy.
Malya FU; Kadioglu H; Bektasoglu HK; Gucin Z; Yildiz S; Guzel M; Erdogan EB; Yucel S; Ersoy YE
J Int Med Res; 2018 Feb; 46(2):626-636. PubMed ID: 29332418
[TBL] [Abstract][Full Text] [Related]
3. [A Case of Severe Drug-Induced Lung Injury during Preoperative Chemotherapy for Breast Cancer in the Early Stages of the COVID-19 Epidemic].
Hirata A; Terasawa R; Takashima Y; Morita S; Kimura K; Iwamoto M; Hayashi M
Gan To Kagaku Ryoho; 2023 Dec; 50(12):1343-1345. PubMed ID: 38247078
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of
Cocciolone V; Cannita K; Tessitore A; Mastroiaco V; Rinaldi L; Paradisi S; Irelli A; Baldi PL; Sidoni T; Ricevuto E; Dal Mas A; Calvisi G; Coletti G; Ciccozzi A; Pizzorno L; Resta V; Bafile A; Alesse E; Ficorella C
Oncotarget; 2018 Jun; 9(44):27380-27396. PubMed ID: 29937992
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review.
Poi MJ; Berger M; Lustberg M; Layman R; Shapiro CL; Ramaswamy B; Mrozek E; Olson E; Wesolowski R
Support Care Cancer; 2013 Oct; 21(10):2679-86. PubMed ID: 23686402
[TBL] [Abstract][Full Text] [Related]
6. A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study.
Antolín S; Mel R; Ramos M; García-Palomo A; Almanza C; de Paz L; Calvo L; Alvarez E; González A; García-Mata J
Clin Transl Oncol; 2011 Sep; 13(9):686-91. PubMed ID: 21865141
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy for "triple negative" breast cancer: a review of current practice and future outlook.
Nahleh Z
Med Oncol; 2010 Jun; 27(2):531-9. PubMed ID: 19513864
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of dose-dense doxorubicin and docetaxel as neoadjunvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer.
García-Mata J; García-Palomo A; Calvo L; Mel R; Cruz JJ; Ramos M
Clin Transl Oncol; 2008 Nov; 10(11):739-44. PubMed ID: 19015070
[TBL] [Abstract][Full Text] [Related]
9. Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival.
Heys SD; Sarkar T; Hutcheon AW
Breast Cancer Res Treat; 2005 Mar; 90(2):169-85. PubMed ID: 15803364
[TBL] [Abstract][Full Text] [Related]
10. [Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
von Minckwitz G; Raab G; Schütte M; Hilfrich J; Blohmer JU; Gerber B; Costa SD; Merkle E; Eidtmann H; Lampe D; Jackisch C; du Bois A; Tulusan AH; Gademann G; Sinn HP; Caputo A; Graf E; Kaufmann M
Zentralbl Gynakol; 2001 Sep; 123(9):497-504. PubMed ID: 11709742
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer.
Cooper BW; Radivoyevitch T; Overmoyer BA; Shenk RR; Pham HT; Samuels JR; Parry MP; Silverman P
Breast Cancer Res Treat; 2006 Jun; 97(3):311-8. PubMed ID: 16344915
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
von Minckwitz G; Raab G; Caputo A; Schütte M; Hilfrich J; Blohmer JU; Gerber B; Costa SD; Merkle E; Eidtmann H; Lampe D; Jackisch C; du Bois A; Kaufmann M
J Clin Oncol; 2005 Apr; 23(12):2676-85. PubMed ID: 15837982
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.
Cardoso F; Ferreira Filho AF; Crown J; Dolci S; Paesmans M; Riva A; Di Leo A; Piccart MJ
Anticancer Res; 2001; 21(1B):789-95. PubMed ID: 11299845
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
